Ryan Butts1, Melanie Davis, Andrew Savage, Ali Burnette, Minoo Kavarana, Scott Bradley, Andrew Atz, Paul J Nietert. 1. 1 Division of Cardiology, Department of Pediatrics, Medical University of South Carolina, Charleston, SC. 2 Department of Public Health Sciences, Medical University of South Carolina, Charleston, SC. 3 Department of Transplant Services, Medical University of South Carolina, Charleston, SC. 4 Department of Surgery, Medical University of South Carolina, Charleston, SC.
Abstract
BACKGROUND: The use of induction therapy in pediatric heart transplantation has increased. The aim of this study was to investigate the effects of induction therapy on graft survival. METHODS: The United Network for Organ Sharing database was queried for isolated pediatric heart transplants from January 1, 1994, to December 31, 2013. Propensity scores for induction treatment were calculated by estimating probability of induction using a logistic regression model. Transplants were then matched between induction treatment groups based on the propensity score, reducing potential biases. Using only propensity score matched transplants, the effect of induction therapy on graft survival was investigated using Cox-proportional hazards. Subgroup analyses were performed based on age, race, recipient cardiac diagnosis, HLA, and recipient panel-reactive antibody (PRA). RESULTS: Of 4565 pediatric primary heart transplants from 1994 to 2013, 3741 had complete data for the propensity score calculation. There were 2792 transplants successfully matched (induction, n = 1396; no induction, n = 1396). There were no significant differences in transplant and pretransplant covariates between induction and no induction groups. In the Cox-proportional hazards model, the use of induction of was not associated with graft loss (hazard ratio [HR], 0.88; 95% confidence interval [95% CI], 0.75-1.01; P = 0.07). In subgroup analyses, induction therapy may be associated with improved survival in patients with PRA greater than 50% (HR, 0.57; 95% CI, 0.34-0.97) and congenital heart disease (HR, 0.78; 95% CI, 0.64-0.96). CONCLUSIONS: Induction therapy is not associated with improved graft survival in primary pediatric heart transplantation. However, in pediatric heart transplant recipients with PRA greater than 50% or congenital heart disease, induction therapy is associated with improved survival.
BACKGROUND: The use of induction therapy in pediatric heart transplantation has increased. The aim of this study was to investigate the effects of induction therapy on graft survival. METHODS: The United Network for Organ Sharing database was queried for isolated pediatric heart transplants from January 1, 1994, to December 31, 2013. Propensity scores for induction treatment were calculated by estimating probability of induction using a logistic regression model. Transplants were then matched between induction treatment groups based on the propensity score, reducing potential biases. Using only propensity score matched transplants, the effect of induction therapy on graft survival was investigated using Cox-proportional hazards. Subgroup analyses were performed based on age, race, recipient cardiac diagnosis, HLA, and recipient panel-reactive antibody (PRA). RESULTS: Of 4565 pediatric primary heart transplants from 1994 to 2013, 3741 had complete data for the propensity score calculation. There were 2792 transplants successfully matched (induction, n = 1396; no induction, n = 1396). There were no significant differences in transplant and pretransplant covariates between induction and no induction groups. In the Cox-proportional hazards model, the use of induction of was not associated with graft loss (hazard ratio [HR], 0.88; 95% confidence interval [95% CI], 0.75-1.01; P = 0.07). In subgroup analyses, induction therapy may be associated with improved survival in patients with PRA greater than 50% (HR, 0.57; 95% CI, 0.34-0.97) and congenital heart disease (HR, 0.78; 95% CI, 0.64-0.96). CONCLUSIONS: Induction therapy is not associated with improved graft survival in primary pediatric heart transplantation. However, in pediatric heart transplant recipients with PRA greater than 50% or congenital heart disease, induction therapy is associated with improved survival.
Authors: Joseph W Rossano; David L S Morales; Farhan Zafar; Susan W Denfield; Jeffrey J Kim; John L Jefferies; William J Dreyer Journal: J Thorac Cardiovasc Surg Date: 2010-05-27 Impact factor: 5.209
Authors: Anne I Dipchand; Richard Kirk; Leah B Edwards; Anna Y Kucheryavaya; Christian Benden; Jason D Christie; Fabienne Dobbels; Lars H Lund; Axel O Rahmel; Roger D Yusen; Josef Stehlik Journal: J Heart Lung Transplant Date: 2013-10 Impact factor: 10.247
Authors: Nicholas Grundy; Jacob Simmonds; Helen Dawkins; Philip Rees; Paul Aurora; Michael Burch Journal: J Heart Lung Transplant Date: 2009-10-28 Impact factor: 10.247
Authors: J K Kirklin; D C Naftel; R C Bourge; C White-Williams; J B Caulfield; M R Tarkka; W L Holman; G L Zorn Journal: Circulation Date: 1992-11 Impact factor: 29.690
Authors: Tajinder P Singh; Carey Faber; Elizabeth D Blume; Sarah Worley; Christopher S Almond; Leslie B Smoot; Shay Dillis; Colleen Nasman; Gerard J Boyle Journal: J Heart Lung Transplant Date: 2010-01-12 Impact factor: 10.247
Authors: S H Kubo; D C Naftel; R M Mills; J O'Donnell; R J Rodeheffer; G B Cintron; J L Kenzora; R C Bourge; J K Kirklin Journal: J Heart Lung Transplant Date: 1995 May-Jun Impact factor: 10.247
Authors: Steven A Webber; David C Naftel; James Parker; Neda Mulla; Ian Balfour; James K Kirklin; Robert Morrow Journal: J Heart Lung Transplant Date: 2003-08 Impact factor: 10.247
Authors: Martin Schweiger; Andreas Zuckermann; Andres Beiras-Fernandez; Michael Berchtolld-Herz; Udo Boeken; Jens Garbade; Stephan Hirt; Manfred Richter; Arjang Ruhpawar; Jan Dieter Schmitto; Felix Schönrath; Rene Schramm; Uwe Schulz; Markus J Wilhelm; Markus J Barten Journal: Ann Transplant Date: 2018-05-15 Impact factor: 1.530